Seegene submits SARS-CoV-2, flu A/B, RSV assay for EUA

Create PDF

“Demand for accurate and available COVID-19 testing remains high across the United States,” Jong-Yoon Chun, PhD, CEO of Seegene, said in a press statement. “This multiplex assay will provide clinicians with the ability to differentiate diagnosis between the common flu and COVID-19. It is also incredibly efficient for labs because they will only need to run a single test versus four different tests. We’re committed to bringing innovative solutions to the market and doing our part in the fight against this pandemic.”

The test is available in Europe and elsewhere around the world.